News

Filter

Current filters:

Regeneron

1 to 9 of 98 results

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

23-02-2015

A Phase IIb study of dupilumab, from Sanofi and Regeneron, has shown that the drug improved patient-reported…

DermatologicalsdupilumabPharmaceuticalRegeneronResearchSanofi

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

EMA accepts Sanofi and Regeneron's MMA for Praluent for review

12-01-2015

French drug major Sanofi and US biotech company Regeneron have announced that the European Medicines…

alirocumabBiotechnologyCardio-vascularEuropeRegeneronRegulationSanofi

Regeneron and Sanofi granted breakthrough designation for dupilumab

Regeneron and Sanofi granted breakthrough designation for dupilumab

25-11-2014

US biotech Regeneron Pharmaceuticals and French pharma major Sanofi have said that the US Food and Drug…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Sanofi and Regeneron’s dupilumab gets Breakthrough designation from FDA

20-11-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to French pharma major…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Bayer/Regeneron’s Eylea approved in Japan for DME

18-11-2014

German pharma major Bayer’s Japanese subsidiary, Bayer Yakuhin, has received approval from the Ministry…

BayerBiotechnologyEyleaJapanOphthalmicsRegeneronRegulation

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

1 to 9 of 98 results

Back to top